The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
USFDA inspection at Emcure Pharmaceuticals API facility
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
TFOS is indicated for the treatment of pulmonary arterial hypertension
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
